Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220227005069/en/



Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE clinical study for its targeted radiotherapy candidate FAP-2286 and a

LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights.



“In 2021, we continued

Novocure’s General Counsel Resigns After 10 Years of Service: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure’s General Counsel Resigns After 10 Years of Service


Novocure (NASDAQ: NVCR) today announced that Todd Longsworth, General Counsel, has resigned. Mr. Longsworth’s last day as General Counsel will be March 31. He will stay onboard as a Senior Legal

NanoString to Webcast Presentation from the 42nd Annual Cowen Health Care Conference: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString to Webcast Presentation from the 42nd Annual Cowen Health Care Conference


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

Chemed Reports Fourth-Quarter 2021 Results:
Chemed Reports Fourth-Quarter 2021 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Agilent to Participate at Cowen and Barclays Health Care Conferences:
Agilent to Participate at Cowen and Barclays Health Care Conferences


Agilent Technologies Inc. (NYSE: A) today announced that Bob McMahon, senior vice president and chief financial officer, will participate in Q&A sessions at the Cowen 42nd Annual Health Care

Agilent and University of Vermont Announce the Agilent Laboratory for Chemical Analysis (ALCA):
Agilent and University of Vermont Announce the Agilent Laboratory for Chemical Analysis (ALCA)


Agilent Technologies Inc. (NYSE: A) and the University of Vermont (UVM) today announced the establishment of the Agilent Laboratory for Chemical Analysis (ALCA). The facility will be a hub for

New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response


Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption

Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Novocure is a global oncology company working to extend survival in some of

Valbiotis veröffentlicht Finanzkommunikationskalender 2022 : https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis veröffentlicht Finanzkommunikationskalender 2022


Regulatory News:



Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung

Valbiotis Presents Its 2022 Financial Communication Calendar: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis Presents Its 2022 Financial Communication Calendar


Regulatory News:



Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA


Regulatory News:



Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides an update on clinical results and timelines

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial

STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the

Cole Edmonson of AMN Healthcare Honored as Staffing Industry Leader, Named to SIA Staffing 100
Cole Edmonson of AMN Healthcare Honored as Staffing Industry Leader, Named to SIA Staffing 100


Cole Edmonson, Chief Clinical Officer of AMN Healthcare (NYSE: AMN), has been honored as one of Staffing Industry Analysts’ 2022 Staffing 100, the leaders of the staffing industry.



The Staffing

Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening:
Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening


Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Company’s clinical development programs and regulatory and

LivaNova Reports Fourth-Quarter and Full-Year 2021 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021.



For the fourth quarter of

DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care published form 20-F for the fiscal year 2021: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care published form 20-F for the fiscal year 2021
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care published form 20-F for the fiscal year 2021
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2021: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2021
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2021
Agilent Reports First-Quarter Fiscal Year 2022 Financial Results:
Agilent Reports First-Quarter Fiscal Year 2022 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the first quarter ended Jan. 31, 2022, an increase of 8% compared to the first quarter of 2021 and up 9% on a core(1)

Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a keynote presentation by Lidia Fonseca, Chief Digital and Technology Officer, Executive Vice

AMN Healthcare Honors MSP Supplier Partners who Help Provide Healthcare Professionals to Nation’s Hospitals and Health Systems
AMN Healthcare Honors MSP Supplier Partners who Help Provide Healthcare Professionals to Nation’s Hospitals and Health Systems


AMN Healthcare, the nation’s leader in total talent solutions for healthcare, today announced the 2021 MSP Supplier Partnership Award winners who help provide quality professionals to AMN Managed